학술논문
Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial.
Document Type
Article
Author
Heaney, Liam G; Busby, John; Hanratty, Catherine E; Djukanovic, Ratko; Woodcock, Ashley; Walker, Samantha M; Hardman, Timothy C; Arron, Joseph R; Choy, David F; Bradding, Peter; Brightling, Christopher E; Chaudhuri, Rekha; Cowan, Douglas C; Mansur, Adel H; Fowler, Stephen J; Niven, Robert M; Howarth, Peter H; Lordan, James L; Menzies-Gow, Andrew; Harrison, Tim W
Source
Lancet Respiratory Medicine; Jan2021, Vol. 9 Issue 1, p57-68, 12p
Subject
Language
ISSN
22132600
Abstract
Copyright of Lancet Respiratory Medicine is the property of Lancet and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)